ITonis

ITonis Net Tangible Assets

The Net Tangible Assets of ITonis (ITNS) as of Oct 28, 2026 is -1.15 M USD. In the previous year, Net Tangible Assets was -1.13 M USD — a change of 1.00% (lower).

Net Tangible Assets

-1.15 MUSD

YoY

1.00%

Last updated:

Net Tangible Assets of ITonis is 2025 -1.15 M USD. Net Tangible Assets of ITonis was 2024 -1.13 M USD. It decreases by 1.00% lower compared to the previous year.

The ITonis Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
-943,157.00 USD
Jan 1, 2019
-1.00 M USD
Jan 1, 2020
-1.05 M USD
Jan 1, 2021
-1.12 M USD
Jan 1, 2022
-1.13 M USD
Jan 1, 2023
-1.05 M USD
Jan 1, 2024
-1.13 M USD
Jan 1, 2025
-1.15 M USD
The ITonis Net Tangible Assets history
YEARNet Tangible AssetsYoY
-1.15 MUSD+1.00%
-1.13 MUSD+7.50%
-1.05 MUSD-6.49%
-1.13 MUSD+0.34%
-1.12 MUSD+6.78%
-1.05 MUSD+4.83%
-1.00 MUSD+6.47%
-943,157.00USD+8.24%
-871,364.00USD+65.78%
-525,629.00USD+18.09%
-445,095.00USD-34.46%
-679,124.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ITonis Stock analysis

What does ITonis do? Itonis, Inc. generates revenue through the distribution of its homeopathic anti-nausea product Emesyl to the medical and pharmaceutical industry. The company markets Emesyl, an over-the-counter and prescription homeopathic preparation, primarily targeting the general public suffering from nausea. Sales occur via Amazon and the company's website Emesyl.com. The firm's subsidiaries, Itonis Holdings, Inc. and Paramount Discoveries, Inc., support its operations in the pharmaceutical sector. Emesyl is positioned as a solution for common ailments, with its availability on Amazon and Emesyl.com enabling direct consumer access. The company's focus on both over-the-counter and prescription products allows it to serve diverse customer segments within the healthcare market. Itonis Pharmaceuticals division handles the production and marketing of these homeopathic preparations. The business model relies on the sale of Emesyl through established retail channels and direct online sales, leveraging the brand's presence on Amazon and its dedicated website. This approach targets individuals seeking nausea relief without requiring a prescription, aligning with the product's over-the-counter status and broad market appeal. ITonis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ITonis stock

Net Tangible Assets of ITonis is -1.15 M USD in 2025.

Net Tangible Assets of ITonis changed from -1.13 M USD to -1.15 M USD, representing a 1.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets ITonis since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's ITonis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ITonis

All Key Metrics — ITonis